Skip to content

Alkermes ALKS Share Buybacks

Share Buybacks at other companies

AbbVie logo
AbbVieABBV
$1.49B+54.9%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$54M-64.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$82.5M+70.9%
Royalty Pharma logo
Royalty PharmaRPRX
$50.1M-92.9%
Viatris logo
ViatrisVTRS
$0-100%
Exelixis logo
ExelixisEXEL
$430.35M+51.6%

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's share buybacks.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alkermes's share buybacks?
Alkermes (ALKS) reported share buybacks of $27.7M in Q1 2026.
What does share buybacks mean?
Cash spent by the company to buy back its own stock.
How do you interpret share buybacks?
Higher repurchases indicate a return of capital to shareholders and a potential signal of management confidence.
How does share buybacks compare across companies?
Mature biotech companies often use this to manage share counts, while early-stage firms rarely do.